-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In 1922, Banting and others discovered and purified insulin and successfully applied it to the treatment of diabetes
Before treatment (left) and after treatment (right) of Elizabeth Hughes, the world's first diabetic patient receiving insulin treatment
However, for patients with type 1 diabetes, it can only be maintained by insulin therapy, which leads to the fundamental problem of the disease-pancreatic islet cells cannot produce insulin by themselves, and there is no other way to solve it
On October 18, 2021, Vertex Pharmaceuticals announced that patients with severe type 1 diabetes have achieved "stable recovery of islet cell function".
Type 1 diabetes is a metabolic disorder syndrome
In addition, because patients must undergo insulin injection therapy, hypoglycemia caused by insulin injection often occurs
Over time, patients' awareness of hypoglycemia may be impaired, which means that they can no longer detect the early signs of hypoglycemia events, which can be life-threatening
The patient has been diagnosed with type 1 diabetes for 40 years and has been dependent on insulin therapy ever since
After treatment, the patient's pancreatic islet cell function "stable recovery"
The safety of this therapy is similar to that of typical immunosuppressive therapy, and there are no reports of serious side effects related to the treatment
Although there is only one successful patient case, this is still enough to prove the feasibility of this therapy, which may be a "game-changing method
VX- 880
VX-880 is a stem cell-derived islet cell replacement therapy
The therapy aims to provide patients with islet cells derived from donor stem cells to produce insulin, thereby replacing insulin injection therapy and long-term care, thereby restoring the body's ability to regulate blood sugar
It is understood that Vertex Pharmaceuticals is developing a pancreatic islet cell encapsulation therapy that does not require immunosuppression for patients, and plans to submit a clinical trial application to the FDA in 2022
(Network resources, for reference only)
